https://orcid.org/0000-0001-8749-6237
Figures & data
Figure 1. Timeline for introduction of systemic treatment (beyond Docetaxel for mCRPC patients).
Table 1. Patient and disease characteristics at diagnosis.
Figure 2. Cumulative proportion of systemic treatment use (ever-use) since diagnosis among men diagnosed with metastatic prostate cancer during 2010–2017.
Table 2. Start of first systemic treatment by time after diagnosis, stratified by diagnostic period. Numbers of patients and percentages are reported n (%).
Figure 3. Sankey diagram showing treatment pathways starting from first use of systemic treatment for men diagnosed with metastatic prostate cancer in Norway during 2010–2014. The width of treatment pathways is proportional to the number of patients who received a given treatment; pathways are only shown for groups of 5 or more.
